GFS Advisors’s VanEck Biotech ETF BBH Stock Holding History

GFS Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,768,590	Closed	-$6K	–	118
2024 Q2	$6K	Buy	+1,768,590	New	+$289M	﹤0.01%	197

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

GFS Advisors's BBH Position: Q3 2024 in Review

GFS Advisors sold out of VanEck Biotech ETF (BBH) in Q3 2024, closing a stake of 1,768,590 shares — an estimated $6K sold.

GFS Advisors first reported a position in BBH in Q2 2024 and held it in 1 quarter. The position peaked at $6K in Q2 2024. 115 funds tracked by Wall St. Rank hold BBH as of Q3 2024.

GFS Advisors reported no remaining VanEck Biotech ETF position as of Q3 2024 after selling out during the quarter.
GFS Advisors sold 1,768,590 VanEck Biotech ETF shares in Q3 2024, an estimated $6K.
GFS Advisors first reported a position in VanEck Biotech ETF in Q2 2024 and held it in 1 quarter.
GFS Advisors's VanEck Biotech ETF position peaked at $6K in Q2 2024.
115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2024.

Based on GFS Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.